A biosimilar medicine is a medicinal product of biological origin that is produced in a living organism following a procedure equivalent to a biological drug and adhering to the same quality criteria, hence the name biosimilars. In short, they are biological drugs that are “equivalent” in terms of quality, efficacy and safety to an innovative reference medicinal product.
According to the report, one driver that will lead to the growth of this market is the rise in number of patent expiries.
Market Analysis and Insights: Global Monoclonal antibodies (mAbs) Biosimilars Market
The global Monoclonal antibodies (mAbs) Biosimilars market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Monoclonal antibodies (mAbs) Biosimilars Scope and Market Size
Monoclonal antibodies (mAbs) Biosimilars market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Monoclonal antibodies (mAbs) Biosimilars market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The following players are covered in this report:
Biocon
Celltrion
Dr. Reddy's Laboratories
Hospira
3SBio
Accord Healthcare
AET Biotech
Allergan
Amega Biotech
Others
Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Type
Erythropoietin (EPO)
Human Growth Hormone (HGH)
Granulocyte- Colony Stimulating Factor (G-CSF)
Monoclonal Antibody (mAb)
Insulin
Interferon (IFN)
Others
Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Application
Anti-Cancer
Anti-Inflammatory/Autoimmune
According to the report, one driver that will lead to the growth of this market is the rise in number of patent expiries.
Market Analysis and Insights: Global Monoclonal antibodies (mAbs) Biosimilars Market
The global Monoclonal antibodies (mAbs) Biosimilars market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Monoclonal antibodies (mAbs) Biosimilars Scope and Market Size
Monoclonal antibodies (mAbs) Biosimilars market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Monoclonal antibodies (mAbs) Biosimilars market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The following players are covered in this report:
Biocon
Celltrion
Dr. Reddy's Laboratories
Hospira
3SBio
Accord Healthcare
AET Biotech
Allergan
Amega Biotech
Others
Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Type
Erythropoietin (EPO)
Human Growth Hormone (HGH)
Granulocyte- Colony Stimulating Factor (G-CSF)
Monoclonal Antibody (mAb)
Insulin
Interferon (IFN)
Others
Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Application
Anti-Cancer
Anti-Inflammatory/Autoimmune
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Monoclonal antibodies (mAbs) Biosimilars Revenue
1.4 Market by Type
1.4.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Erythropoietin (EPO)
1.4.3 Human Growth Hormone (HGH)
1.4.4 Granulocyte- Colony Stimulating Factor (G-CSF)
1.4.5 Monoclonal Antibody (mAb)
1.4.6 Insulin
1.4.7 Interferon (IFN)
1.4.8 Others
1.5 Market by Application
1.5.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Application: 2020 VS 2026
1.5.2 Anti-Cancer
1.5.3 Anti-Inflammatory/Autoimmune
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Perspective (2015-2026)
2.2 Global Monoclonal antibodies (mAbs) Biosimilars Growth Trends by Regions
2.2.1 Monoclonal antibodies (mAbs) Biosimilars Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Monoclonal antibodies (mAbs) Biosimilars Historic Market Share by Regions (2015-2020)
2.2.3 Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Monoclonal antibodies (mAbs) Biosimilars Market Growth Strategy
2.3.6 Primary Interviews with Key Monoclonal antibodies (mAbs) Biosimilars Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Market Size
3.1.1 Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Revenue (2015-2020)
3.1.2 Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Players (2015-2020)
3.1.3 Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Monoclonal antibodies (mAbs) Biosimilars Market Concentration Ratio
3.2.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Monoclonal antibodies (mAbs) Biosimilars Revenue in 2019
3.3 Monoclonal antibodies (mAbs) Biosimilars Key Players Head office and Area Served
3.4 Key Players Monoclonal antibodies (mAbs) Biosimilars Product Solution and Service
3.5 Date of Enter into Monoclonal antibodies (mAbs) Biosimilars Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Monoclonal antibodies (mAbs) Biosimilars Historic Market Size by Type (2015-2020)
4.2 Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
5.2 Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Monoclonal antibodies (mAbs) Biosimilars Market Size (2015-2020)
6.2 Monoclonal antibodies (mAbs) Biosimilars Key Players in North America (2019-2020)
6.3 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020)
6.4 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
7 Europe
7.1 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size (2015-2020)
7.2 Monoclonal antibodies (mAbs) Biosimilars Key Players in Europe (2019-2020)
7.3 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020)
7.4 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
8 China
8.1 China Monoclonal antibodies (mAbs) Biosimilars Market Size (2015-2020)
8.2 Monoclonal antibodies (mAbs) Biosimilars Key Players in China (2019-2020)
8.3 China Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020)
8.4 China Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
9 Japan
9.1 Japan Monoclonal antibodies (mAbs) Biosimilars Market Size (2015-2020)
9.2 Monoclonal antibodies (mAbs) Biosimilars Key Players in Japan (2019-2020)
9.3 Japan Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020)
9.4 Japan Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Monoclonal antibodies (mAbs) Biosimilars Market Size (2015-2020)
10.2 Monoclonal antibodies (mAbs) Biosimilars Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020)
10.4 Southeast Asia Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
11 India
11.1 India Monoclonal antibodies (mAbs) Biosimilars Market Size (2015-2020)
11.2 Monoclonal antibodies (mAbs) Biosimilars Key Players in India (2019-2020)
11.3 India Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020)
11.4 India Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Monoclonal antibodies (mAbs) Biosimilars Market Size (2015-2020)
12.2 Monoclonal antibodies (mAbs) Biosimilars Key Players in Central & South America (2019-2020)
12.3 Central & South America Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020)
12.4 Central & South America Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Biocon
13.1.1 Biocon Company Details
13.1.2 Biocon Business Overview
13.1.3 Biocon Monoclonal antibodies (mAbs) Biosimilars Introduction
13.1.4 Biocon Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020))
13.1.5 Biocon Recent Development
13.2 Celltrion
13.2.1 Celltrion Company Details
13.2.2 Celltrion Business Overview
13.2.3 Celltrion Monoclonal antibodies (mAbs) Biosimilars Introduction
13.2.4 Celltrion Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
13.2.5 Celltrion Recent Development
13.3 Dr. Reddy's Laboratories
13.3.1 Dr. Reddy's Laboratories Company Details
13.3.2 Dr. Reddy's Laboratories Business Overview
13.3.3 Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Introduction
13.3.4 Dr. Reddy's Laboratories Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
13.3.5 Dr. Reddy's Laboratories Recent Development
13.4 Hospira
13.4.1 Hospira Company Details
13.4.2 Hospira Business Overview
13.4.3 Hospira Monoclonal antibodies (mAbs) Biosimilars Introduction
13.4.4 Hospira Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
13.4.5 Hospira Recent Development
13.5 3SBio
13.5.1 3SBio Company Details
13.5.2 3SBio Business Overview
13.5.3 3SBio Monoclonal antibodies (mAbs) Biosimilars Introduction
13.5.4 3SBio Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
13.5.5 3SBio Recent Development
13.6 Accord Healthcare
13.6.1 Accord Healthcare Company Details
13.6.2 Accord Healthcare Business Overview
13.6.3 Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Introduction
13.6.4 Accord Healthcare Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
13.6.5 Accord Healthcare Recent Development
13.7 AET Biotech
13.7.1 AET Biotech Company Details
13.7.2 AET Biotech Business Overview
13.7.3 AET Biotech Monoclonal antibodies (mAbs) Biosimilars Introduction
13.7.4 AET Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
13.7.5 AET Biotech Recent Development
13.8 Allergan
13.8.1 Allergan Company Details
13.8.2 Allergan Business Overview
13.8.3 Allergan Monoclonal antibodies (mAbs) Biosimilars Introduction
13.8.4 Allergan Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
13.8.5 Allergan Recent Development
13.9 Amega Biotech
13.9.1 Amega Biotech Company Details
13.9.2 Amega Biotech Business Overview
13.9.3 Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Introduction
13.9.4 Amega Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
13.9.5 Amega Biotech Recent Development
13.10 Others
13.10.1 Others Company Details
13.10.2 Others Business Overview
13.10.3 Others Monoclonal antibodies (mAbs) Biosimilars Introduction
13.10.4 Others Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
13.10.5 Others Recent Development
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Monoclonal antibodies (mAbs) Biosimilars Revenue
1.4 Market by Type
1.4.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Erythropoietin (EPO)
1.4.3 Human Growth Hormone (HGH)
1.4.4 Granulocyte- Colony Stimulating Factor (G-CSF)
1.4.5 Monoclonal Antibody (mAb)
1.4.6 Insulin
1.4.7 Interferon (IFN)
1.4.8 Others
1.5 Market by Application
1.5.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Application: 2020 VS 2026
1.5.2 Anti-Cancer
1.5.3 Anti-Inflammatory/Autoimmune
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Perspective (2015-2026)
2.2 Global Monoclonal antibodies (mAbs) Biosimilars Growth Trends by Regions
2.2.1 Monoclonal antibodies (mAbs) Biosimilars Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Monoclonal antibodies (mAbs) Biosimilars Historic Market Share by Regions (2015-2020)
2.2.3 Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Monoclonal antibodies (mAbs) Biosimilars Market Growth Strategy
2.3.6 Primary Interviews with Key Monoclonal antibodies (mAbs) Biosimilars Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Market Size
3.1.1 Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Revenue (2015-2020)
3.1.2 Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Players (2015-2020)
3.1.3 Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Monoclonal antibodies (mAbs) Biosimilars Market Concentration Ratio
3.2.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Monoclonal antibodies (mAbs) Biosimilars Revenue in 2019
3.3 Monoclonal antibodies (mAbs) Biosimilars Key Players Head office and Area Served
3.4 Key Players Monoclonal antibodies (mAbs) Biosimilars Product Solution and Service
3.5 Date of Enter into Monoclonal antibodies (mAbs) Biosimilars Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Monoclonal antibodies (mAbs) Biosimilars Historic Market Size by Type (2015-2020)
4.2 Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
5.2 Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Monoclonal antibodies (mAbs) Biosimilars Market Size (2015-2020)
6.2 Monoclonal antibodies (mAbs) Biosimilars Key Players in North America (2019-2020)
6.3 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020)
6.4 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
7 Europe
7.1 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size (2015-2020)
7.2 Monoclonal antibodies (mAbs) Biosimilars Key Players in Europe (2019-2020)
7.3 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020)
7.4 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
8 China
8.1 China Monoclonal antibodies (mAbs) Biosimilars Market Size (2015-2020)
8.2 Monoclonal antibodies (mAbs) Biosimilars Key Players in China (2019-2020)
8.3 China Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020)
8.4 China Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
9 Japan
9.1 Japan Monoclonal antibodies (mAbs) Biosimilars Market Size (2015-2020)
9.2 Monoclonal antibodies (mAbs) Biosimilars Key Players in Japan (2019-2020)
9.3 Japan Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020)
9.4 Japan Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Monoclonal antibodies (mAbs) Biosimilars Market Size (2015-2020)
10.2 Monoclonal antibodies (mAbs) Biosimilars Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020)
10.4 Southeast Asia Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
11 India
11.1 India Monoclonal antibodies (mAbs) Biosimilars Market Size (2015-2020)
11.2 Monoclonal antibodies (mAbs) Biosimilars Key Players in India (2019-2020)
11.3 India Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020)
11.4 India Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Monoclonal antibodies (mAbs) Biosimilars Market Size (2015-2020)
12.2 Monoclonal antibodies (mAbs) Biosimilars Key Players in Central & South America (2019-2020)
12.3 Central & South America Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020)
12.4 Central & South America Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Biocon
13.1.1 Biocon Company Details
13.1.2 Biocon Business Overview
13.1.3 Biocon Monoclonal antibodies (mAbs) Biosimilars Introduction
13.1.4 Biocon Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020))
13.1.5 Biocon Recent Development
13.2 Celltrion
13.2.1 Celltrion Company Details
13.2.2 Celltrion Business Overview
13.2.3 Celltrion Monoclonal antibodies (mAbs) Biosimilars Introduction
13.2.4 Celltrion Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
13.2.5 Celltrion Recent Development
13.3 Dr. Reddy's Laboratories
13.3.1 Dr. Reddy's Laboratories Company Details
13.3.2 Dr. Reddy's Laboratories Business Overview
13.3.3 Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Introduction
13.3.4 Dr. Reddy's Laboratories Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
13.3.5 Dr. Reddy's Laboratories Recent Development
13.4 Hospira
13.4.1 Hospira Company Details
13.4.2 Hospira Business Overview
13.4.3 Hospira Monoclonal antibodies (mAbs) Biosimilars Introduction
13.4.4 Hospira Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
13.4.5 Hospira Recent Development
13.5 3SBio
13.5.1 3SBio Company Details
13.5.2 3SBio Business Overview
13.5.3 3SBio Monoclonal antibodies (mAbs) Biosimilars Introduction
13.5.4 3SBio Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
13.5.5 3SBio Recent Development
13.6 Accord Healthcare
13.6.1 Accord Healthcare Company Details
13.6.2 Accord Healthcare Business Overview
13.6.3 Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Introduction
13.6.4 Accord Healthcare Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
13.6.5 Accord Healthcare Recent Development
13.7 AET Biotech
13.7.1 AET Biotech Company Details
13.7.2 AET Biotech Business Overview
13.7.3 AET Biotech Monoclonal antibodies (mAbs) Biosimilars Introduction
13.7.4 AET Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
13.7.5 AET Biotech Recent Development
13.8 Allergan
13.8.1 Allergan Company Details
13.8.2 Allergan Business Overview
13.8.3 Allergan Monoclonal antibodies (mAbs) Biosimilars Introduction
13.8.4 Allergan Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
13.8.5 Allergan Recent Development
13.9 Amega Biotech
13.9.1 Amega Biotech Company Details
13.9.2 Amega Biotech Business Overview
13.9.3 Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Introduction
13.9.4 Amega Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
13.9.5 Amega Biotech Recent Development
13.10 Others
13.10.1 Others Company Details
13.10.2 Others Business Overview
13.10.3 Others Monoclonal antibodies (mAbs) Biosimilars Introduction
13.10.4 Others Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
13.10.5 Others Recent Development
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
